致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: AMCO United Holding Limited 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 HKD | | 400,000,000 | 本月 ...

Revenue Performance - Medical products revenue for the fiscal year 2024 reached HKD 25.57 million, a 16.5% increase from HKD 21.94 million in fiscal year 2023[5] - Custom components for medical equipment saw a significant revenue increase of 86%, driven by a shift towards comprehensive systems like Continuous Glucose Monitoring (CGM)[8] - Sales of blood collection tubes and equipment dropped from HKD 30.43 million in fiscal year 2022 to HKD 14.13 million in fiscal year 2023, a decline of 53.6%[7] - Revenue from pandemic-related products fell to zero in fiscal year 2023, a 100% decrease from HKD 16.34 million in fiscal year 2022, due to normalized demand post-COVID-19[6] Product Development and Expansion - The company plans to expand its product offerings to include surgical instruments, orthopedic tools, imaging equipment, and disinfection products[11] - The company intends to launch 2 to 3 new co-developed products by 2026, including surgical instrument kits and imaging equipment accessories[14] - The newly obtained production license is a strategic expansion of the existing medical business segment, significantly broadening the product portfolio with new devices and components, including infusion and transfusion devices, nursing and care equipment, and protective gear[15] - The production license allows the company to market and sell a diverse range of medical devices in China, covering categories such as active and passive surgical instruments, orthopedic surgical instruments, medical imaging equipment, and more[16] Regulatory Compliance and Quality Control - The company is focusing on diversifying its product lines while ensuring regulatory compliance with certifications like CE and FDA[11] - The company emphasizes compliance with strict quality and regulatory standards to ensure the highest levels of safety and effectiveness for its medical products[28] - The production facilities have received FDA certification, reflecting the company's commitment to adhering to strict regulatory frameworks[28] - The company emphasizes strict quality control and regulatory compliance in all operations, whether internal or outsourced[30] Market Strategy and Partnerships - The company aims to achieve product registration and distribution permits in Shandong by August 2025, marking a significant milestone for market entry[12] - The company is actively seeking partnerships with subcontractors that have existing certifications to expedite market entry without significant capital expenditure[12] - The company anticipates obtaining additional provincial registrations in China by the fourth quarter of 2026 to expand its geographical coverage[13] - The company will adopt a data-driven regional expansion strategy to optimize service delivery and enhance commitment to hospital clients[34] Operational Capacity and Team - The company has established an 8-member dedicated operations team led by Mr. Dai Zhongliang, who has over ten years of experience in the medical products industry, to manage and monitor all manufacturing processes[27] - The company has a maximum annual production capacity of approximately 5 million units at its existing facility in Dongguan, China[31] - The business model under the production license remains unchanged, ensuring rapid expansion of the product range while maintaining effective operational strategies[17] Financial Projections and Market Outlook - The Chinese healthcare market is projected to grow at a compound annual growth rate of approximately 12-14%, reaching over $250 billion by 2030[32] - The company plans to achieve estimated sales of RMB 20 million by December 2025 through strategic partnerships with clients introduced by a new management team member[33] - The board is optimistic about business prospects due to strong market demand and strategic initiatives taken[32] - The establishment of a new subsidiary in Jinan, Shandong, aims to strengthen the company's market presence in China[33] Customer Engagement and Sales Strategy - The sales and marketing department is tasked with customer engagement, handling inquiries, and coordinating sales orders to ensure timely processing and delivery[23] - The company aims to enhance its core business by providing a more comprehensive product suite to meet broader customer needs and generate additional revenue streams[15] - The company will expand its customer base to include hospital clients, diversifying revenue sources and strengthening market position[33]

致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | | | 本月底 ...

Core Viewpoint - JunTai Holdings (00630.HK) announced the appointment of Li Sisi as an independent non-executive director, effective from November 14, 2025, along with his membership in the audit committee, nomination committee, and remuneration committee [1] Group 1 - JunTai Holdings has made a significant governance change by appointing Li Sisi to its board [1] - The appointment includes roles in key committees, indicating a strategic move towards enhancing corporate governance [1] - The effective date of the appointment is set for November 14, 2025, allowing for a transition period [1]

Group 1 - The company, JunTai Holdings (00630), announced the appointment of Ms. Li Sisi as an independent non-executive director effective from November 14, 2025 [1] - Ms. Li will also serve as a member of the Audit Committee, Nomination Committee, and Remuneration Committee under the board [1]

Core Viewpoint - JunTai Holdings (00630) announced the appointment of Ms. Li Sisi as an independent non-executive director, effective from November 14, 2025, along with her membership in the audit committee, nomination committee, and remuneration committee [1] Group 1 - Ms. Li Sisi has been appointed as an independent non-executive director [1] - The appointment is effective from November 14, 2025 [1] - Ms. Li will also serve on the audit committee, nomination committee, and remuneration committee [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：630） 委任獨立非執行董事、審核委員會、 薪酬委員會及提名委員會成員 * 僅供識別 1 於本公告日期，除上文所披露者外，(i) 李女士在過去三年並無持有任何其他重大 任命及資格或於其證券於香港或海外之任何證券市場上市之其他上市公司擔任任 何董事職務；(ii)李女士並無於本公司或本集團其他成員公司擔任任何其他職務； (iii) 李女士與任何董事、本公司高級管理人員、主要或控股股東（具有上市規則所 賦予之涵義）並無任何關係；及(iv)並無任何進一步資料須根據上市規則第13.51(2)(h) 至(v)條之規定予以披露，且並無任何有關委任李女士之其他事宜須敦請本公司股 東垂注。 董事會謹此熱烈歡迎李女士加入本公司。 遵守上市規則第3.10(1) 條、3.10(2) 條、3.21條及3.25條以及上市規則附錄14所 載企業管治守則之守則條文第A.5.1條 茲提述本公司日 ...

（於百慕達註冊成立之有限公司） （股份代號：630） 董事名單與其角色和職能 雋泰控股有限公司董事會（「董事會」）成員載列如下：– 歐陽銘賢先生 （主席） 張亨鑫先生 李斯斯女士 提名委員會： 張亨鑫先生 （主席） 郭鎮輝先生 李斯斯女士 執行董事： 賈明暉先生 （主席） 張亨鑫先生 獨立非執行董事： 歐陽銘賢先生 郭鎮輝先生 李斯斯女士 董事會設立3個委員會，各委員會成員載列如下：– 審核委員會： 歐陽銘賢先生 （主席） 郭鎮輝先生 李斯斯女士 薪酬委員會： 香港，二零二五年十一月十四日 * 僅供識別 ...

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00630 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.05 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: AMCO United Holding Limited 呈交日 ...

Core Viewpoint - JunTai Holdings (00630) announced the resignation of Ms. Ye Mengmei as an independent non-executive director and member of the company's remuneration committee, nomination committee, and audit committee, effective from October 2, 2025 [1] Group 1 - Ms. Ye Mengmei is resigning to allocate more time to other matters [1] - The resignation will take effect on October 2, 2025 [1]